/SRZN
SRZN Stock - Surrozen, Inc.
Healthcare|BiotechnologyNASDAQ
$21.76+1.26%
+$0.27 (+1.26%) • Dec 19
89
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
High Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.100
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.95
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+76.9%upside
Target: $38.49
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for SRZN
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$21.54 – $21.98
TARGET (TP)$38.50
STOP LOSS$20.02
RISK/REWARD1:9.6
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.62
52W High$24.94
52W Low$5.90
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $10.65M | N/A | $12.50M | N/A | N/A |
| Gross Profit | $10.65M | $-27,230,000 | $9.23M | $-3,297,000 | $-2,929,000 |
| Gross Margin | 100.0% | N/A | 73.8% | N/A | N/A |
| Operating Income | $-25,539,000 | $-45,780,000 | $-44,339,000 | $-54,391,000 | $-32,807,000 |
| Net Income | $-63,564,000 | $-43,042,000 | $-36,004,000 | $-52,510,000 | $-32,625,000 |
| Net Margin | -596.6% | N/A | -288.0% | N/A | N/A |
| EPS | $-21.67 | $-21.33 | $-15.55 | $-23.40 | $-41.12 |
Company Overview
Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair and regeneration. It is developing tissue-specific antibodies with application across various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043 a tissue-specific R-spondin mimetic for the treatment of severe liver disease; and SZN-1326, a bi-specific full-length human antibody that directly modulates Wnt signaling in target tissue by binding to particular Frizzled and LRP receptors that are expressed in intestinal crypts. Surrozen, Inc. was founded in 2015 and is headquartered in South San Francisco, California.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
2
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
2 Bullish0 Neutral/Bearish
Price Targets
$39
Average Target
↑ 76.9% Upside
Now
$32
Low
$39
Average
$45
High
Based on 2 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| January 30th 2025 | H.C. Wainwright | Initiation | Buy | $32 |
| January 3rd 2025 | Guggenheim | Upgrade | Buy | $45 |
Earnings History & Surprises
SRZNBeat Rate
59%
Last 17 quarters
Avg Surprise
-24.3%
EPS vs Estimate
Beats / Misses
10/7
Last 12 quarters
Latest EPS
$-3.61
Q4 2025
EPS Surprise History
Q1 24
-47.0%
$-4.41vs$-3.00
Q2 24
+0.2%
$-4.24vs$-4.25
Q3 24
+44.8%
$-1.54vs$-2.79
Q4 24
+84.1%
$-0.44vs$-2.77
Q1 25
-258.3%
$-9.10vs$-2.54
Q2 25
-187.2%
$-3.13vs$-1.09
Q3 25
+7.3%
$-1.14vs$-1.23
Q4 25
-208.5%
$-3.61vs$-1.17
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 30, 2026 | $-1.41 | — | — | — |
Q4 2025 | Nov 7, 2025 | $-1.17 | $-3.61 | -208.5% | ✗ MISS |
Q3 2025 | Aug 8, 2025 | $-1.23 | $-1.14 | +7.3% | ✓ BEAT |
Q2 2025 | May 9, 2025 | $-1.09 | $-3.13 | -187.2% | ✗ MISS |
Q1 2025 | Mar 31, 2025 | $-2.54 | $-9.10 | -258.3% | ✗ MISS |
Q4 2024 | Nov 6, 2024 | $-2.77 | $-0.44 | +84.1% | ✓ BEAT |
Q3 2024 | Aug 12, 2024 | $-2.79 | $-1.54 | +44.8% | ✓ BEAT |
Q2 2024 | May 8, 2024 | $-4.25 | $-4.24 | +0.2% | ✓ BEAT |
Q1 2024 | Mar 27, 2024 | $-3.00 | $-4.41 | -47.0% | ✗ MISS |
Q4 2023 | Nov 8, 2023 | $-4.20 | $-4.35 | -3.6% | ✗ MISS |
Q3 2023 | Aug 9, 2023 | $-6.00 | $-4.65 | +22.5% | ✓ BEAT |
Q2 2023 | May 10, 2023 | $-5.10 | $-7.20 | -41.2% | ✗ MISS |
Q1 2023 | Mar 22, 2023 | $-6.75 | $-0.45 | +93.3% | ✓ BEAT |
Q4 2022 | Nov 14, 2022 | $-6.45 | $-5.70 | +11.6% | ✓ BEAT |
Q3 2022 | Aug 11, 2022 | $-6.90 | $-6.00 | +13.0% | ✓ BEAT |
Q2 2022 | May 11, 2022 | $-8.10 | $-3.45 | +57.4% | ✓ BEAT |
Q1 2022 | Mar 24, 2022 | $-7.80 | $-5.25 | +32.7% | ✓ BEAT |
Q4 2021 | Nov 15, 2021 | $-0.38 | $-0.51 | -34.2% | ✗ MISS |
Q3 2021 | Aug 6, 2021 | — | $-0.36 | — | — |
Q3 2021 | Jul 15, 2021 | — | $-0.37 | — | — |
Latest News
Surrozen Appoints Andrew Maleki CFO, Effective Nov. 12, Succeeding Charles Williams
➖ NeutralBenzinga•Nov 7, 2025, 09:14 PM
Surrozen Q3 EPS $(8.36) Misses $(1.14) Estimate, Sales $983.000K Down From $10.000M YoY
📉 NegativeBenzinga•Nov 7, 2025, 09:09 PM
Surrozen Announces Termination Of Collaboration Agreement With TCGFB, Effective November 13, 2025; No Side To Incur Any Termination Penalties
➖ NeutralBenzinga•Oct 17, 2025, 08:25 PM
Surrozen Files For Common Stock Offering Of Up To $50M
📉 NegativeBenzinga•Aug 29, 2025, 09:03 PM
Frequently Asked Questions about SRZN
What is SRZN's current stock price?
Surrozen, Inc. (SRZN) is currently trading at $21.76 per share. The stock has moved +1.26% today.
What is the analyst price target for SRZN?
The average analyst price target for SRZN is $38.50, based on 1 analyst.
What sector is Surrozen, Inc. in?
Surrozen, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is SRZN's market cap?
Surrozen, Inc. has a market capitalization of $0.19 billion, making it a small-cap company.
Does SRZN pay dividends?
No, Surrozen, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorAGEN
Agenus Inc.
$3.44
Mkt Cap: $0.1B
ATOS
Atossa Therapeutics, Inc.
$0.73
Mkt Cap: $0.1B
CGTX
Cognition Therapeutics, Inc.
$1.54
Mkt Cap: $0.1B
GLSI
Greenwich LifeSciences, Inc.
$13.01
Mkt Cap: $0.2B
IMMX
Immix Biopharma, Inc.
$5.72
Mkt Cap: $0.2B
IRD
Opus Genetics, Inc.
$2.00
Mkt Cap: $0.1B
SEER
Seer, Inc.
$1.79
Mkt Cap: $0.1B
TIL
Instil Bio, Inc.
$11.27
Mkt Cap: $0.1B
TVGN
Tevogen Bio Holdings Inc.
$0.38
Mkt Cap: $0.1B
VTGN
VistaGen Therapeutics, Inc.
$0.78
Mkt Cap: $0.0B
Explore stocks similar to SRZN for comparison